Affiance Financial LLC Sells 557 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Apr 1st, 2023

Affiance Financial LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 8.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,169 shares of the company’s stock after selling 557 shares during the quarter. Affiance Financial LLC’s holdings in Johnson & Johnson were worth $1,090,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in JNJ. DORCHESTER WEALTH MANAGEMENT Co raised its position in Johnson & Johnson by 8.6% during the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock worth $14,975,000 after acquiring an additional 5,327 shares in the last quarter. Cantor Fitzgerald Investment Advisor L.P increased its holdings in shares of Johnson & Johnson by 88.9% in the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock valued at $31,049,000 after purchasing an additional 82,429 shares during the last quarter. AMI Investment Management Inc. increased its holdings in shares of Johnson & Johnson by 8.8% in the first quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock valued at $3,244,000 after purchasing an additional 1,475 shares during the last quarter. Equitable Holdings Inc. increased its holdings in shares of Johnson & Johnson by 4.9% in the first quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock valued at $8,095,000 after purchasing an additional 2,119 shares during the last quarter. Finally, USS Investment Management Ltd increased its holdings in shares of Johnson & Johnson by 2.4% in the first quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock valued at $152,488,000 after purchasing an additional 20,528 shares during the last quarter. 67.94% of the stock is owned by institutional investors.

Insider Transactions at Johnson & Johnson

In related news, insider James D. Swanson sold 1,062 shares of Johnson & Johnson stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the sale, the insider now owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 0.35% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the topic of several research reports. StockNews.com initiated coverage on shares of Johnson & Johnson in a report on Thursday, March 16th. They issued a “strong-buy” rating on the stock. SVB Leerink decreased their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research note on Friday, January 20th. Citigroup upped their price target on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research note on Monday, December 12th. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 25th. Finally, UBS Group began coverage on shares of Johnson & Johnson in a research report on Tuesday. They set a “neutral” rating and a $164.00 price objective for the company. Eight analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $173.67.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $155.00 on Friday. The company has a market cap of $403.66 billion, a price-to-earnings ratio of 23.00, a price-to-earnings-growth ratio of 2.64 and a beta of 0.54. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $186.69. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35. The firm has a 50 day moving average of $158.02 and a 200-day moving average of $167.12.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, beating the consensus estimate of $2.22 by $0.13. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The business had revenue of $23.71 billion for the quarter, compared to analysts’ expectations of $23.90 billion. During the same period last year, the business earned $2.13 EPS. The business’s revenue was down 4.4% on a year-over-year basis. On average, equities analysts forecast that Johnson & Johnson will post 10.5 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st were paid a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.92%. The ex-dividend date was Friday, February 17th. Johnson & Johnson’s payout ratio is 67.06%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.